On Friday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) opened higher 27.92% from the last session, before settling in for the closing price of $35.89. Price fluctuations for CRNX have ranged from $24.10 to $62.53 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -12.11%. Company’s average yearly earnings per share was noted -29.43% at the time writing. With a float of $87.07 million, this company’s outstanding shares have now reached $94.13 million.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Crinetics Pharmaceuticals Inc is 7.54%, while institutional ownership is 107.60%. The most recent insider transaction that took place on Sep 26 ’25, was worth 574,240. Before that another transaction happened on Sep 26 ’25, when Company’s Officer proposed sale 4,000 for $45.00, making the entire transaction worth $180,000.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.96 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.91) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.11% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Check out the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). In the past quarter, the stock posted a quick ratio of 17.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3110.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.11, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -5.05 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Compared to the last year’s volume of 1.04 million, its volume of 3.19 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 75.99%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 95.12%, which indicates a significant increase from 92.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.94 in the past 14 days, which was higher than the 1.46 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.78, while its 200-day Moving Average is $34.92. Nevertheless, the first resistance level for the watch stands at $48.57 in the near term. At $51.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $55.52. If the price goes on to break the first support level at $41.62, it is likely to go to the next support level at $37.33. Now, if the price goes above the second support level, the third support stands at $34.67.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
There are currently 94,176K shares outstanding in the company with a market cap of 4.32 billion. Presently, the company’s annual sales total 1,040 K according to its annual income of -298,410 K. Last quarter, the company’s sales amounted to 1,030 K and its income totaled -115,640 K.
